NEW YORK (GenomeWeb) – Clearbridge BioMedics said today that it has registered its target cell enrichment device, the ClearCell FX1 system, as a Class I medical device with the US Food and Drug Administration.

ClearCell is a label-free, microfluidics-based liquid biopsy device that allows for the enrichment of target cells from blood. The system had previously been CE-marked for in vitro diagnostic use in Europe, and was available in China as a China FDA-approved device. It was commercially launched in 2015.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.